Epidemiological characterization of users in two methadone maintenance programs in Colombia
DOI:
https://doi.org/10.21134/934Keywords:
Methadone, Heroin Dependence, Opioid-Related Disorders, TramadolAbstract
Objective: to characterize epidemiologically the users of two methadone maintenance programs in two cities of Colombia. Methods: cross-sectional analytical observational study that analyzed the clinical records of patients in two methadone maintenance programs in Medellin and Cali during the year 2022. Descriptive and bivariate analysis was performed. Results: 250 patients between 17 and 67 years of age participated with a median age of 33 years (RIC = 29 - 38). 80.4% (n=201) were men, heroin was the main opioid for which they were admitted with a proportion of 88.8% (n=222), followed by tramadol; 27.6% (n=69) shared syringes for intravenous use and 92.0% (n=230) reported consuming two or more drugs at the same time, with marijuana and cocaine being the main substances consumed simultaneously with opioids. The most prevalent comorbidities were: personality disorders, hepatitis C infection and illegal behavior. Conclusions: intravenous heroin use and syringe sharing were associated with an increased risk of hepatitis C and HIV. A novel finding is the admission of individuals to the program for exclusive use of tramadol, which, although it is related to global trends in the phenomenon of abuse of opioids for medical use, has not been a frequent event in the Colombian context.
Downloads
References
Arum, C., Fraser, H., Artenie, A. A., Bivegete, S., Trickey, A., Alary, M., Astemborski, J., Iversen, J., Lim, A. G., MacGregor, L., Morris, M., Ong, J. J., Platt, L., Sack-Davis, R., van Santen, D. K., Solomon, S. S., Sypsa, V., Valencia, J., Van Den Boom, W., … Strathdee, S. A. (2021). Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. The Lancet Public Health, 6(5), e309-e323. https://doi.org/10.1016/S2468-2667(21)00013-X
Arve, K. (2023). “You get stuck in it”: Young people’s accounts of attempting to quit non-medical tramadol use. Nordic Studies on Alcohol and Drugs, 40(4), 355-370. https://doi.org/10.1177/14550725231160330
Choi, M., Bins, G., Konakanchi, J., & Sethi, R. (2021). Tramadol’s Potential as a Gateway to Opioid Use Disorder. Kansas Journal of Medicine, 14, 17-18. https://doi.org/10.17161/kjm.vol1413513
Delargy, I., Crowley, D., & Van Hout, M. C. (2019). Twenty years of the methadone treatment protocol in Ireland: Reflections on the role of general practice. Harm Reduction Journal, 16(1), 5. https://doi.org/10.1186/s12954-018-0272-4
Diaper, A. M., Law, F. D., & Melichar, J. K. (2014). Pharmacological strategies for detoxification. British journal of clinical pharmacology, 77(2), 302–314. https://doi.org/10.1111/bcp.12245
Espelt, A., Marí-Dell’Olmo, M., Penelo, E., & Bosque-Prous, M. (2016). Estimación de la Razón de Prevalencia con distintos modelos de Regresión: Ejemplo de un estudio internacional en investigación de las adicciones. Adicciones, 29(2), 105. https://doi.org/10.20882/adicciones.823
Fairley, M., Humphreys, K., Joyce, V. R., Bounthavong, M., Trafton, J., Combs, A., Oliva, E. M., Goldhaber-Fiebert, J. D., Asch, S. M., Brandeau, M. L., & Owens, D. K. (2021). Cost-effectiveness of Treatments for Opioid Use Disorder. JAMA Psychiatry, 78(7), 767. https://doi.org/10.1001/jamapsychiatry.2021.0247
Fundación Salutia - Centro de estudios, innovación e investigación en salud. (s. f.). Estudio de prevalencia de VIH, hepatitis virales, sífilis y comportamientos asociados en las personas que se inyectan drogas Bogotá, Medellín, Santiago de Cali y el área conurbada de Pereira y Dosquebradas. https://www.minjusticia.gov.co/programas-co/ODC/Documents/Publicaciones/Informe%20final%20de%20resultados_digital%20(1).pdf
Garcia-Orjuela, M. G., Alarcon-Franco, L., Sanchez-Fernandez, J. C., Agudelo, Y., & Zuluaga, A. F. (2016). Dependence to legally prescribed opioid analgesics in a university hospital in Medellin-Colombia: an observational study. BMC Pharmacology and Toxicology, 17(1), 42. https://doi.org/10.1186/s40360-016-0087-4
González, G., Giraldo, L. F., DiGirolamo, G., Rey, C. F., Correa, L. E., Cano, A. M., & Romero-González, M. (2019). Enfrentando el problema emergente de consumo de heroína en Colombia: los nuevos programas de tratamiento asistido con metadona. Revista Colombiana de Psiquiatría, 48(2), 96-104. https://doi.org/10.1016/j.rcp.2017.07.004
Goodwin, S. R., Moskal, D., Marks, R. M., Clark, A. E., Squeglia, L. M., & Roche, D. J. O. (2022). A Scoping Review of Gender, Sex and Sexuality Differences in Polysubstance Use in Adolescents and Adults. Alcohol and Alcoholism, 57(3), 292-321. https://doi.org/10.1093/alcalc/agac006
John, W. S., Zhu, H., Mannelli, P., Schwartz, R. P., Subramaniam, G. A., & Wu, L.-T. (2018). Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients. Drug and Alcohol Dependence, 187, 79-87. https://doi.org/10.1016/j.drugalcdep.2018.01.035
La Heroína en Colombia, Producción, uso e impacto en la salud pública - Análisis de la evidencia y recomendaciones de política. (2015). https://www.minjusticia.gov.co/programas-co/ODC/Publicaciones/Publicaciones/CO03132015-la_heroina_en_colombia_produccion_impacto_salud.pdf
Lobato Parra, Eva; López-Núñez, Carla; Cano-García, & Francisco Javier. «Adicción a opiáceos en adultos con dolor crónico y diferencias de sexo: una revisión sistemática». Psicosomí tica y Psiquiatría, 2024, n.º 28, https://doi.org/10.60940/PsicosomPsiquiatrnum280914.
Marsh, J. C., Park, K., Lin, Y. A., & Bersamira, C. (2018). Gender differences in trends for heroin use and nonmedical prescription opioid use, 2007-2014. Journal of substance abuse treatment, 87, 79–85. https://doi.org/10.1016/j.jsat.2018.01.001
Ministerio de Salud y Protección Social; Ministerio de Justicia y del Derecho en cooperación técnica con la Oficina de las Naciones Unidas Contra la Droga y el Delito. Lineamientos técnicos para la implementación de programas de mantenimiento con metadona -PMM- en Colombia. Bogotá; 2018. (s. f.). https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IGUB/lineamientos-pmm-metadona.pdf
Mohd Razali, N., & Bee Wah, Y. (2011). Power comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling tests. En Journal of Statistical Modeling and Analytics (Vol. 2, Número 1).
Mukau, L., Wormley, K., Tomaszewski, C., Ahmad, B., Vohra, R., & Herring, A. A. (2022). Buprenorphine for High-dose Tramadol Dependence: A Case Report of Successful Outpatient Treatment. Clinical practice and cases in emergency medicine, 6(1), 71–74. https://doi.org/10.5811/cpcem.2021.12.54602
Rostamâ€Abadi, Y., Gholami, J., Aminâ€Esmaeili, M., Safarcherati, A., Mojtabai, R., Ghadirzadeh, M. R., Rahimi, H., & Rahimiâ€Movaghar, A. (2020). Tramadol use and public health consequences in Iran: a systematic review and metaâ€analysis. Addiction, 115(12), 2213-2242. https://doi.org/10.1111/add.15059
Serdarevic, M., Striley, C. W., & Cottler, L. B. (2017). Sex differences in prescription opioid use. Current opinion in psychiatry, 30(4), 238–246. https://doi.org/10.1097/YCO.0000000000000337
Sarkar, S., Nebhinani, N., Singh, S. M., Mattoo, S. K., & Basu, D. (2012). Tramadol Dependence: A Case Series from India. Indian Journal of Psychological Medicine, 34(3), 283-285. https://doi.org/10.4103/0253-7176.106038
Soyka, M., Strehle, J., Rehm, J., Bühringer, G., & Wittchen, H.-U. (2017). Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample. European Addiction Research, 23(2), 97-105. https://doi.org/10.1159/000468518
UNODC, World Drug Report 2023 (United Nations publication, 2023). (s. f.). www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html
Wilson, D. P., Donald, B., Shattock, A. J., Wilson, D., & Fraser-Hurt, N. (2015). The cost-effectiveness of harm reduction. International Journal of Drug Policy, 26, S5–S11. https://doi.org/10.1016/j.drugpo.2014.11.007
Winstock, A. R., Borschmann, R., & Bell, J. (2014). The non-medical use of tramadol in the UK: findings from a large community sample. International Journal of Clinical Practice, 68(9), 1147-1151. https://doi.org/10.1111/ijcp.12429
Zhang, H., & Liu, Z. (2013). The Investigation of Tramadol Dependence with No History of Substance Abuse: A Cross-Sectional Survey of Spontaneously Reported Cases in Guangzhou City, China. BioMed Research International, 2013, 1-6. https://doi.org/10.1155/2013/283425
Zhou, B., Cai, G. F., Lv, H. K., Xu, S. F., Wang, Z. T., Jiang, Z. G., Hu, C. G., & Chen, Y. Di. (2019). Factors Correlating to the Development of Hepatitis C Virus Infection among Drug Users—Findings from a Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 16(13), 2345. https://doi.org/10.3390/ijerph16132345
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Health and Addictions Journal/Revista Salud y Drogas

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors publishing in this journal agree to the journal's statement of ethical principles and to the following terms:
The rights of the published material shall belong to their respective authors. Articles published in HAAJ may be used under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license, and may be read, copied, distributed, printed, searched, or linked to in the full text of this journal without prior permission from the publisher or author, provided that HAAJ and the authors are acknowledged and not used for commercial purposes.
Authors may include the work in institutional repositories or other publications as long as this journal is acknowledged and properly cited.
The HAAJ editorial team encourages authors to disseminate their published work through any means (conferences, classes, lectures, talks, etc.) and/or platforms (social networks, repositories, websites, etc.).
HAAJ follows the Core Practices of COPE (Committee on Publication Ethics).